Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin vs Metformin on Myocardial Tissue in T2D and Obesity
NCT06059287Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Renji Hospital. Primary endpoint: Extra-cellular volume fraction at 24 weeks. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06059287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059287.